FDA Brief

FDA warning letters and recalls, in plain English.

FDA posts 62 warning letters and 463 recalls a month as long legal documents. We translate each one and email you the day FDA acts on a supplier, a competitor or a topic you follow.

Latest serious letter, posted Nov 17

FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

FDA inspected Natural Essentials' drug manufacturing facility in Streetsboro, Ohio, from June 22 to 26, 2026. FDA found significant current good manufacturing practice (CGMP) violations for finished OTC drugs, including inadequate investigations of failing test results, unsuitable microbial test methods, missing identity testing on incoming components, and incomplete laboratory records. FDA reviewed the company's August 11, 2026 response to the Form FDA 483 inspection observations and found it inadequate.

Company
Natural Essentials, Inc.
Risk
High risk
Response due
Dec 1

Recent warning letters

All 3,819 letters
  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  4. Q’s American Best Trading Inc.

    FDA warned Q’s American Best Trading that it lacked required foreign supplier verification for imported cinnamon, corn, and instant noodles.

    High risk
  5. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  6. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  7. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  8. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk

Know the day FDA acts on a company you depend on

Watch a contract manufacturer, an ingredient supplier, a competitor or a topic like "sterility" or "Listeria". Free for 3 watches.

Set up free alerts